Key Highlights

  • ImmuPharma plc (LSE:IMM) declined 5.58% on 2 October 2026.
  • The company aims to secure a commercial licensing deal for its P140 autoimmune platform during 2026.
  • Half-year results showed an overall loss of £4.7 million, including a £3.36 million finance loss on derivative revaluation.
  • A £6.47 million fundraise in 2026 is expected to provide a cash runway into the second half of 2028.

Why Is ImmuPharma (LSE:IMM) in Focus Today?

ImmuPharma plc (LSE:IMM) fell 5.58% on 2 October 2026. The specialist drug discovery and development company focuses on peptide-based therapeutics, with two key assets: P140, an autoimmune technology platform, and Kapiglucagon, a treatment being developed for type 1 diabetes.

With the final quarter of 2026 now under way, investors are increasingly focused on whether the company can deliver its stated objective of securing a value-enhancing commercial deal for P140 this year.

Key Reasons Behind the 5.58% Decline on 2 October 2026

No single company announcement was clearly identifiable behind the day’s fall. The decline appears linked to the following factors.

Deal timing pressure: ImmuPharma has repeatedly said a P140 licensing deal is targeted for 2026. Previously, the shares fell when the deal timeframe was extended into 2026. With only three months of the year remaining, any perceived risk of further delay weighs on sentiment.

Half-year loss: Results published on 15 September 2026 showed an operating loss of £1.1 million, slightly improved from £1.2 million, but an overall loss of £4.7 million due to a £3.36 million finance loss on the Revaluation of a derivative financial asset.

Low period-end cash: Cash at 30 June 2026 stood at £0.7 million, although the company expects access to funds from its fundraising arrangements to extend its runway.

Volatile trading history: The shares have traded in a wide range over the past year, reflecting the speculative nature of small biotech stocks.

Pipeline Overview

P140: P140 is ImmuPharma’s lead asset and core value driver. It is designed to modulate the immune system in autoimmune diseases such as lupus. In March 2026, the company received its first Combined Search and Examination Report on a UK Patent application filed in August 2025, supporting its intellectual property position. Discussions with potential partners are advancing with the goal of a deal in 2026.

Kapiglucagon: The company is accelerating development of Kapiglucagon for type 1 diabetes, a market where improved glucagon treatments for severe hypoglycaemia are in demand.

Funding Position

In March and April 2026, ImmuPharma raised approximately £6.47 million through a subscription and retail offer, with shareholders approving the related resolutions with around 91% and 89% support. Together with existing funds, this is expected to provide a cash runway into the second half of 2028, reducing near-term funding pressure.

What Investors Are Watching

P140 licensing deal: Announcement of a commercial agreement and its financial terms.

Kapiglucagon milestones: Development and regulatory progress.

Patent progress: Further strengthening of intellectual property.

Cash management: Use of funds and any changes to the runway.

Conclusion

The 5.58% decline in ImmuPharma plc (LSE:IMM) on 2 October 2026 reflects growing pressure to deliver the P140 licensing deal targeted for 2026, along with a headline loss driven by derivative revaluation. The extended cash runway reduces funding risk, but the share price is likely to remain closely tied to news on partnering discussions in the coming months.